AmideBio secures $2.7M SBIR grant

BOULDER — Biopharmaceutical company AmideBio LLC has received a $2.69 million grant for research into a potential treatment for a rare pediatric disease.

The Small Business Innovation Research grant comes from the National Institute of Diabetes and Digestive and Kidney Diseases for preclinical development of a treatment for congenital hyperinsulinism, which affects newborns and results in persistent hypoglycemia.

The disease can lead to serious neurological complications, including seizures and brain damage.

This two-year grant will allow AmideBio to perform work necessary to support the filing of an Investigational New Drug application with the U.S. Food and Drug Administration. AmideBio also will file for orphan-drug and rare pediatric disease designation with the FDA.

Dr. Diva D. De León-Crutchlow, chief of the Division of Endocrinology and Diabetes and director of the Congenital Hyperinsulinism Center at Children’s Hospital of Philadelphia, will serve as a co-principal investigator on the grant.

“We are honored to receive this Phase IIB SBIR grant from the NIH. It is an acknowledgement of the strength of the data generated under the Phase II SBIR and the company’s focus on bringing a product to market that truly will meet the needs of these children suffering from HI,” Pawel Fludzinski, CEO and president of AmideBio, said in a written statement. “The collaboration with Dr. Diva D. De León-Crutchlow at CHOP, who is a world leader in the treatment of HI, has been pivotal to

on Facebook on LinkedIn